Sign In
Media & Investors
Skip Navigation LinksSanten > EMEA > Media & Investors > News > European marketing authorization application for Ikervis® has been filed to the EMA for the treatment of Dry Eye Disease
Contact
Santen Pharmaceutical welcomes your inquiries and opinions.

European marketing authorization application for Ikervis® has been filed to the EMA for the treatment of Dry Eye Disease

12/6/2013

​​​​​​​​Evry (France), Osaka (Japan), December 6, 2013 – Santen, a global pharmaceutical company specialized in the fields of ophthalmology, today announces that a European Marketing Authorization Application (MAA) for Ikervis® has been filed to the European Medicines Agency (EMA) for the treatment of Dry Eye Disease. In doing so, the EMA will begin its regulatory review process of the MAA. The application includes safety and efficacy data from Ikervis®’s clinical program which was conducted in Europe.


The filing of the application for Ikervis® to the European Medicines Agency is an important step forward in the development of the Santen’s Dry Eye franchise.​​

About Santen Pharmaceutical Co. Ltd.

www.santen.com

Founded in 1890, Santen is a global pharmaceutical company specialized in the fields of ophthalmology and ant-rheumatics, which is headquartered in Osaka, Japan. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe, and Asia, including its Emeryville, California based Santen Inc., its Tampere, Finland based Santen OY, its Evry, France based Santen SAS and Novagali Innovation Center, its Suzhou, China based Santen Pharmaceutical (China) Co., Ltd. and its Bangalore, India based Santen India Private Limited. ​

Media relations

Nicolas Merigeau – NewCap. – nmerigeau@newcap.fr​ – Tel: +33-1-4471-9498​

​Santen Pharmaceutical contact

Geneviève Garrigos
Director
Corporate Communication Europe
Santen SAS
1 rue Pierre Fontaine, Genavenir IV,
F-91058 Evry France
Tel: +33-6-6554-6019    

  

Takashi Hibi
General Manager
Corporate Communication Group
Santen Pharmaceutical, Co., Ltd.
4-20 Ofukacho,
Kita-ku, Osaka 530-8552 Japan
Tel: +81-6-4802-3827​

Forward-looking Statements

Information provided in this press release contains so-called “forward looking statements”. The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by governments in Japan and other nations concerning medical system, drug pricing and other systems, as well as fluctuations in market variables such as interest and foreign exchange rates.​